基于人群的乳腺癌与卵巢癌患者队列的基因检测及结果
研究纳入2013至2014年美国加州和佐治亚州SEER登记的全部20岁以上乳腺癌或卵巢癌患者,链接四家实验室的胚系癌症基因检测结果。乳腺癌患者24.1%、卵巢癌患者30.9%有检测结果;卵巢癌中黑人及无保险者检测率较低。乳腺癌和卵巢癌中可干预致病性变异患病率分别为7.8%和14.5%。
要点
- 乳腺癌患者中24.1%、卵巢癌患者中30.9%有基因检测结果。
- 卵巢癌中黑人检测率21.6%低于白人33.8%,无保险者20.8%低于有保险者35.3%。
- 乳腺癌可干预致病性变异患病率7.8%,卵巢癌为14.5%。
核心结论
- 在两个大型、多样化州中接受临床检测的乳腺癌和卵巢癌患者,可干预致病性变异患病率为8%至15%。
- 卵巢癌患者中存在大量检测缺口和差异,是改进的目标。
研究设计与样本
- 研究纳入2013至2014年间在加利福尼亚州和佐治亚州诊断为乳腺癌或卵巢癌的所有20岁及以上女性,并报告至覆盖全州人口的SEER登记。
- SEER数据与四家实验室的胚系癌症基因检测结果链接,这四家实验室完成了几乎全部胚系癌症基因检测。
- 在基因水平分析检测使用情况和结果。
主要发现
- 共有77,085例乳腺癌患者和6,001例卵巢癌患者。
- 乳腺癌患者中24.1%、卵巢癌患者中30.9%有基因检测结果。
- 卵巢癌患者中,黑人检测率为21.6%(95%CI 18.1%至25.4%),白人检测率为33.8%(95%CI 32.3%至35.3%)。
- 卵巢癌患者中,无保险者检测率为20.8%(95%CI 15.5%至26.9%),有保险者检测率为35.3%(95%CI 33.8%至36.9%)。
- 乳腺癌患者中常见致病性变异为BRCA1(3.2%)、BRCA2(3.1%)、CHEK2(1.6%)、PALB2(1.0%)、ATM(0.7%)和NBN(0.4%)。
关键数值与推荐
- 卵巢癌患者中常见致病性变异为BRCA1(8.7%)、BRCA2(5.8%)、CHEK2(1.4%)、BRIP1(0.9%)、MSH2(0.8%)和ATM(0.6%)。
- 致病性变异的种族/民族差异包括BRCA1(卵巢癌:白人7.2%,95%CI 5.9%至8.8%;西班牙裔16.1%,95%CI 11.8%至21.2%)。
- 致病性变异的种族/民族差异包括CHEK2(乳腺癌:白人2.3%,95%CI 1.8%至2.8%;黑人0.1%,95%CI 0%至0.8%)。
- 当检测当前指南指定的与其癌症类型相关的所有基因时,7.8%的乳腺癌患者和14.5%的卵巢癌患者有致病性变异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Genetic testing for cancer risk has expanded rapidly. We examined clinical genetic testing and results among population-based patients with breast and ovarian cancer. METHODS: The study included all women 20 years of age or older diagnosed with breast or ovarian cancer in California and Georgia between 2013 and 2014 and reported to the SEER registries covering the entire state populations. SEER data were linked to results from four laboratories that performed nearly all germline cancer genetic testing. Testing use and results were analyzed at the gene level. RESULTS: There were 77,085 patients with breast cancer and 6,001 with ovarian cancer. Nearly one quarter of those with breast cancer (24.1%) and one third of those with ovarian cancer (30.9%) had genetic test results. Among patients with ovarian cancer, testing was lower in blacks (21.6%; 95% CI, 18.1% to 25.4%; v whites, 33.8%; 95% CI, 32.3% to 35.3%) and uninsured patients (20.8%; 95% CI, 15.5% to 26.9%; v insured patients, 35.3%; 95% CI, 33.8% to 36.9%). Prevalent pathogenic variants in patients with breast cancer were BRCA1 (3.2%), BRCA2 (3.1%), CHEK 2 (1.6%), PALB2 (1.0%), ATM (0.7%), and NBN (0.4%); in patients with ovarian cancer, prevalent pathogenic variants were BRCA1 (8.7%), BRCA2 (5.8%), CHEK2 (1.4%), BRIP1 (0.9%), MSH2 (0.8%), and ATM (0.6%). Racial/ethnic differences in pathogenic variants included BRCA1 (ovarian cancer: whites, 7.2%; 95% CI, 5.9% to 8.8%; v Hispanics, 16.1%; 95% CI, 11.8% to 21.2%) and CHEK2 (breast cancer: whites, 2.3%; 95% CI, 1.8% to 2.8%; v blacks, 0.1%; 95% CI, 0% to 0.8%). When tested for all genes that current guidelines designate as associated with their cancer type, 7.8% of patients with breast cancer and 14.5% of patients with ovarian cancer had pathogenic variants. CONCLUSION: Clinically-tested patients with breast and ovarian cancer in two large, diverse states had 8% to 15% prevalence of actionable pathogenic variants. Substantial testing gaps and disparities among patients with ovarian cancer are targets for improvement.
引用
- Kurian AW, Ward KC, Howlader N, et al. Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. J Clin Oncol. 2019. PMID: 30964716. doi:10.1200/JCO.18.01854
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。